Globus Medical Raises Profit Outlook as Spine Growth Accelerates
Globus Medical (NYSE: GMED) raised its 2026 non-GAAP EPS outlook to $4.95-$5.05 from $4.70-$4.80, while reaffirming revenue guidance of $3.18B-$3.22B. Q2 revenue rose 5.9% to $789.6M; non-GAAP diluted EPS rose 55.8% to $1.34. GAAP EPS fell due to a 2025 Nevro acquisition gain and margin expanded.
How this was made
The 30-second read
Why it matters
The company increased its 2026 non-GAAP EPS range while keeping revenue guidance unchanged, implying margin and operating leverage are the key swing factors for earnings.
Market read
A concrete guidance raise with supporting segment growth and margin expansion provides a tradable catalyst for GMED positioning into the next earnings cycle.
What to watch
The outlook raise is non-GAAP; traders may scrutinize integration progress of Nevro and whether margin expansion is sustainable beyond near-term synergies.
Background
Globus Medical reported Q2 revenue growth and is integrating its Nevro acquisition while emphasizing spine and surgical technology as core growth drivers.
Ticker impact
Globus Medical raised 2026 non-GAAP EPS outlook to $4.95-$5.05 as spine sales strengthened and margins expanded.
Likely near-term positive bias as traders reprice 2026 EPS range and margin/operating leverage assumptions.
The article discloses a specific full-year non-GAAP EPS range increase plus supporting Q2 margin expansion and spine revenue growth, which are direct inputs to valuation and positioning.
Market effects
Signals strength in spine and surgical technology demand, potentially improving sentiment for musculoskeletal medtech peers with similar procedure mix.
International growth (reported +18%, constant-currency +16.2%) may shift attention toward non-US procedure demand and distribution strength.
Improved margins and operating leverage reinforce the broader medtech narrative that procedure volumes plus mix can offset earnings volatility.
Counterpoint
GAAP earnings were pressured by a one-time 2025 acquisition bargain-purchase gain comparison, so the quality of the earnings improvement may be less robust on a GAAP basis.
Key entities
- companyGlobus Medical Inc.
Raised 2026 non-GAAP EPS outlook to $4.95-$5.05, citing stronger spine sales and margin expansion.
- executiveKeith Pfeil
CEO attributed momentum to U.S. Spine and International Spine strength.
- executiveKyle Kline
CFO linked record non-GAAP net income to revenue growth, margin expansion, operating leverage, and acquisition synergies.
